{"id":2291,"date":"2026-06-11T08:00:00","date_gmt":"2026-06-11T11:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2291"},"modified":"2026-06-11T08:00:00","modified_gmt":"2026-06-11T11:00:00","slug":"rss-clinica-medicina-infectologia-hospitalar-iras-bsi-cauti-vap-ssi-clabsi-stewardship-antimicrobiano-cih","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-infectologia-hospitalar-iras-bsi-cauti-vap-ssi-clabsi-stewardship-antimicrobiano-cih\/","title":{"rendered":"RSS IRAS: BSI, CAUTI, VAP, SSI, stewardship"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores hospitalares que reduzem RSS a descarte de luva e m\u00e1scara<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 hospitais com infectologia hospitalar IRAS Infec\u00e7\u00e3o Relacionada Assist\u00eancia Sa\u00fade<\/strong> + BSI bloodstream infection + CLABSI central line-associated + CAUTI catheter-associated urinary + VAP ventilator-associated pneumonia + SSI surgical site infection + CDI Clostridioides difficile<\/strong> + stewardship antimicrobiano AMS Antimicrobial Stewardship Program<\/strong> + CIH Comiss\u00e3o Infec\u00e7\u00e3o Hospitalar Lei 6.437+Portaria 2.616\/1998+RDC 36\/2013<\/strong> + CDC NHSN National Healthcare Safety Network + ANVISA INSAR Indicadores Nacionais SAR<\/strong> + dashboard tempo real Power BI+Tableau<\/strong> + bundle preven\u00e7\u00e3o SHEA+IDSA<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (sangue cateter venoso central CVC ponta+hemocultura+urocultura+aspirado traqueal+swab nasal+SARS-CoV-2+influenza+RSV+VRSA+MRSA+VRE+ESBL+KPC+NDM+CRE) + Grupo A2 (escarro+aspirado bronco-alveolar BAL+secre\u00e7\u00e3o drenagem cir\u00fargica+swab perirretal CRE colonization screening) + Grupo B (antimicrobiano vancomicina+linezolida+daptomicina+ceftarolina+ceftazidima-avibactam Avycaz+ceftolozana-tazobactam Zerbaxa+meropenem-vaborbactam Vabomere+imipenem-relebactam Recarbrio+cefiderocol Fetroja+plazomicina+eravaciclina Xerava+Lefamulina Xenleta+omadaciclina Nuzyra+contezolida Lista B\/C5) + Grupo E (perfuro CVC PICC line + arterial line + Swan-Ganz + cateter Foley + sonda enteral + tubo OT + dispositivo m\u00e9dico contaminado).<\/p>\n

Para o gestor que opera ou planeja gest\u00e3o IRAS hospitalar, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos IRAS<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS IRAS tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
BSI+CLABSI<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nCVC+PICC+hemocultura<\/td>\n<\/tr>\n
CAUTI urin\u00e1ria<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nFoley+urocultura+IDSA<\/td>\n<\/tr>\n
VAP pneumonia<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nTubo OT+aspirado<\/td>\n<\/tr>\n
SSI s\u00edtio cir\u00fargico<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nDrenagem+swab+SHEA<\/td>\n<\/tr>\n
CDI+stewardship+resistente<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nC. difficile+CRE+KPC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 14-42 kg\/dia<\/strong> em hospital com gest\u00e3o IRAS madura.<\/p>\n

BSI + CLABSI + CAUTI + VAP + SSI + CDI: o est\u00e1gio diagn\u00f3stico<\/h2>\n

A primeira camada \u00e9 IRAS principais. Padr\u00e3o setorial inclui (a) BSI bloodstream infection + CLABSI central line-associated<\/strong> com hemocultura aer\u00f3bia+anaer\u00f3bia + ponta CVC cultura semi-quantitativa Maki + Staph aureus+coagulase-negative+Pseudomonas+Klebsiella+Acinetobacter+Candida + bundle CHG chlorhexidine + maximum barrier precautions + daily review necessity + ANVISA RDC 36\/2013; (b) CAUTI catheter-associated urinary tract infection<\/strong> com urocultura \u226510\u2075 CFU\/mL + sintomas + Foley indwelling + bundle indication + sterile insertion + closed system + early removal + IDSA guidelines; (c) VAP ventilator-associated pneumonia<\/strong> com BAL bronco-alveolar lavage + protected specimen brush PSB + tracheal aspirate \u226510\u2075 CFU\/mL + bundle HOB head of bed elevation 30-45\u00b0 + DVT prophylaxis + PUD + sedation vacation + early extubation + ATS\/IDSA; (d) SSI surgical site infection<\/strong> com superficial+deep+organ\/space + 30 dias p\u00f3s-cir + 90 dias implante + bundle CHG bath + nasal mupirocin Staph + redosing antibiotic + temperature normothermia + glycemic control + SHEA\/IDSA; (e) CDI Clostridioides difficile<\/strong> com diarreia \u22653\/24h + toxin EIA+GDH+NAAT PCR + Bristol stool scale + tratamento vancomicina oral 125mg q6h + fidaxomicina Dificid Merck 200mg q12h + bezlotoxumab Zinplava monoclonal + transplante microbiota fecal FMT + Vowst SER-109 oral spores SDD.<\/p>\n

Hospital com BSI+CAUTI+VAP+SSI+CDI maduro escala bundle compliance 95+%<\/strong> + escala redu\u00e7\u00e3o IRAS 30-50% global<\/strong> + escala FMT cura recurrent CDI 80-90%<\/strong>. Como discutimos no post sobre infectologia<\/a>, IRAS \u00e9 base.<\/p>\n

Stewardship antimicrobiano + CRE+KPC+NDM+novos antibi\u00f3ticos: o est\u00e1gio resist\u00eancia<\/h2>\n

A segunda camada \u00e9 stewardship+resist\u00eancia. Padr\u00e3o setorial inclui (a) AMS Antimicrobial Stewardship Program<\/strong> SHEA+IDSA+CDC + 4 elementos lideran\u00e7a+expertise+a\u00e7\u00e3o+rastreamento + ASP team infectologista+farmac\u00eautico+microbiologista+epidemiologista; (b) stewardship intervention<\/strong> com prospective audit feedback + formulary restriction + IV-to-PO switch + de-escalation + duration optimization + indication review + diagnostic stewardship; (c) CRE Carbapenem-Resistant Enterobacteriaceae KPC+NDM+OXA-48+VIM+IMP<\/strong> com colonization screening swab perirretal + isolamento contato + cohort + active surveillance ASP + WHO Priority Pathogens List; (d) novos antibi\u00f3ticos \u03b2-lactam\/\u03b2-lactamase inhibitor<\/strong> com ceftazidima-avibactam Avycaz Pfizer KPC+OXA-48 + meropenem-vaborbactam Vabomere Melinta KPC + imipenem-relebactam Recarbrio Merck KPC + ceftolozana-tazobactam Zerbaxa MDR Pseudomonas + cefiderocol Fetroja Shionogi sider\u00f3foro OXA-48+NDM+VIM; (e) outros novos<\/strong> plazomicina Zemdri aminoglicos\u00eddeo CRE + eravaciclina Xerava Tetraphase tetraciclina + omadaciclina Nuzyra Paratek + lefamulina Xenleta Nabriva pleuromutilina CAP + contezolida MIM-China linezolida-like + tedizolida Sivextro Lista C5.<\/p>\n

Hospital com stewardship+CRE+novos maduro escala redu\u00e7\u00e3o AMR uso 20-30%<\/strong> + escala redu\u00e7\u00e3o resist\u00eancia KPC 30-50%<\/strong> + acessa Avycaz+Vabomere+Recarbrio+Fetroja CRE arsenal<\/strong>. Conex\u00e3o com biosseguran\u00e7a<\/a>.<\/p>\n

CIH Comiss\u00e3o Infec\u00e7\u00e3o Hospitalar + ANVISA INSAR + CDC NHSN + dashboard real-time: o est\u00e1gio governan\u00e7a<\/h2>\n

A terceira camada \u00e9 governan\u00e7a. Padr\u00e3o setorial inclui (a) CIH Comiss\u00e3o Infec\u00e7\u00e3o Hospitalar<\/strong> Portaria 2.616\/1998 + Lei 6.437 + Lei 9.431\/1997 + RDC 36\/2013 + CCIH Comiss\u00e3o Controle Infec\u00e7\u00e3o Hospitalar obrigat\u00f3ria + SCIH Servi\u00e7o Controle + respons\u00e1vel t\u00e9cnico m\u00e9dico+enfermeiro; (b) ANVISA INSAR Indicadores Nacionais SAR<\/strong> com BSI\/CLABSI taxa 1000 dias-cateter + CAUTI taxa 1000 dias-Foley + VAP taxa 1000 dias-VM + SSI cirurgia limpa-contaminada-contaminada-suja + CDI taxa + AMR resistance rate + reporting obrigat\u00f3rio SUS+ANS; (c) CDC NHSN National Healthcare Safety Network<\/strong> com benchmarking nacional EUA + SIR Standardized Infection Ratio + observed\/expected ratio + hospital safety grade Leapfrog + Magnet Recognition Program; (d) dashboard real-time IRAS<\/strong> com Power BI Microsoft + Tableau Salesforce + EpiInfo CDC + LabSoft Conexa + WHO Global Antimicrobial Resistance Surveillance System GLASS + alarme autom\u00e1tico + drill-down case-by-case; (e) stakeholder governan\u00e7a<\/strong> com infectologista hospitalar + epidemiologista + farmac\u00eautico cl\u00ednico + microbiologista cl\u00ednico + enfermeiro CCIH + Diretor Cl\u00ednico + Conselho Administrativo + ANVISA + ANS + CIH municipal+estadual + WHO+OPS.<\/p>\n

Hospital com CIH+ANVISA INSAR+NHSN+dashboard maduro escala SIR Standardized Infection Ratio <1<\/strong> + acessa benchmarking NHSN comparative<\/strong> + escala dashboard real-time alarme autom\u00e1tico<\/strong>. Conex\u00e3o com auditoria controle<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade IRAS<\/h2>\n

Hospital sem CIH estruturada.<\/strong> 1-2 fluxos. Custo mensal R$ 15.000-40.000<\/strong> mas perda de stewardship+CRE+novos antibi\u00f3ticos.<\/p>\n

Hospital com CIH m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 30.000-75.000<\/strong>, captura BSI+CAUTI+VAP.<\/p>\n

Hospital com IRAS completo 5 fluxos.<\/strong> BSI+CAUTI+VAP+SSI+CDI+stewardship + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 55.000-130.000<\/strong>, efic\u00e1cia 95%, ROI 1.000-3.000% via captura SIR <1 + bundle compliance 95% + redu\u00e7\u00e3o IRAS 30-50% + AMR -20-30%.<\/p>\n

Os tr\u00eas erros que aparecem em IRAS<\/h2>\n

O primeiro \u00e9 a subdimensionamento novos antibi\u00f3ticos CRE Lista B\/C5<\/strong>. Sem segrega\u00e7\u00e3o Avycaz+Vabomere+Recarbrio+Zerbaxa+Fetroja+plazomicina+eravaciclina+omadaciclina+lefamulina + Lista B\/C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro R$ 5-50k\/dia\/paciente.<\/p>\n

O segundo \u00e9 a mistura BSI + CAUTI + VAP + SSI + CDI<\/strong>. Confunde rastreabilidade IRAS + impossibilita NHSN reporting + bundle SHEA\/IDSA padronizado + risco subnotifica\u00e7\u00e3o INSAR.<\/p>\n

O terceiro \u00e9 a falta de protocolo CRE colonization screening + isolamento contato<\/strong>. Sem swab perirretal + active surveillance + cohort + isolamento contato = surto KPC\/NDM\/OXA-48 + risco mortalidade 30-50% bacteremia CRE.<\/p>\n

A regula\u00e7\u00e3o de RSS IRAS no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com infectologia hospitalar especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A ANVISA Boletim Seguran\u00e7a Paciente IRAS<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS IRAS 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a BSI+CLABSI hemocultura+ponta CVC Maki+Staph aureus+CoNS+Pseudomonas+Klebsiella+Acinetobacter+Candida+bundle CHG+maximum barrier+daily review+ANVISA RDC 36\/2013, CAUTI urocultura \u226510\u2075+Foley+bundle indication+sterile+closed+early removal+IDSA, VAP BAL+PSB+aspirado \u226510\u2075+bundle HOB 30-45\u00b0+DVT+PUD+sedation vacation+ATS\/IDSA, SSI superficial+deep+organ\/space+30\/90d+CHG bath+mupirocin Staph+redosing antibiotic+normothermia+glycemic control+SHEA\/IDSA, CDI Clostridioides difficile diarreia+toxin EIA+GDH+NAAT PCR+vancomicina oral+fidaxomicina Dificid Merck+bezlotoxumab Zinplava+FMT+Vowst SER-109 SDD, stewardship AMS SHEA+IDSA+CDC 4 elementos+ASP team+prospective audit+formulary restriction+IV-to-PO+de-escalation+CRE swab perirretal+isolamento contato+WHO Priority+Avycaz+Vabomere+Recarbrio+Zerbaxa+Fetroja Shionogi sider\u00f3foro+plazomicina Zemdri+eravaciclina Xerava+omadaciclina Nuzyra+lefamulina Xenleta+contezolida+tedizolida Sivextro Lista C5, governan\u00e7a CIH Portaria 2.616\/1998+Lei 6.437+Lei 9.431+RDC 36+CCIH+SCIH+ANVISA INSAR+CDC NHSN SIR+Leapfrog+Magnet+dashboard Power BI+Tableau+EpiInfo CDC+LabSoft Conexa+WHO GLASS.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS IRAS: BSI + CAUTI + VAP + SSI + CLABSI + stewardship. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3128,3126,943,3127],"class_list":["post-2291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-cih","tag-infectologia-hospitalar","tag-iras","tag-stewardship"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2291"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2291\/revisions"}],"predecessor-version":[{"id":4368,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2291\/revisions\/4368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}